These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36589601)

  • 21. Systemic lupus erythematosus and pregnancy: the challenge of improving antenatal care and outcomes.
    Pastore DEA; Costa ML; Surita FG
    Lupus; 2019 Oct; 28(12):1417-1426. PubMed ID: 31551036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pregnancy outcomes in patients with systemic lupus erythematosus: a retrospective review of 62 pregnancies at a single tertiary center in South Korea.
    Park EJ; Jung H; Hwang J; Kim H; Lee J; Ahn JK; Cha HS; Koh EM
    Int J Rheum Dis; 2014 Nov; 17(8):887-97. PubMed ID: 25267089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients With Systemic Lupus Erythematosus.
    Kim JW; Jung JY; Kim HA; Yang JI; Kwak DW; Suh CH
    J Rheumatol; 2021 May; 48(5):707-716. PubMed ID: 33060317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study.
    Golder V; Huq M; Franklyn K; Calderone A; Lateef A; Lau CS; Lee ALH; Navarra STV; Godfrey T; Oon S; Hoi AYB; Morand EF; Nikpour M
    Semin Arthritis Rheum; 2017 Jun; 46(6):798-803. PubMed ID: 28216192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women.
    Liu J; Zhao Y; Song Y; Zhang W; Bian X; Yang J; Liu D; Zeng X; Zhang F
    J Matern Fetal Neonatal Med; 2012 Mar; 25(3):261-6. PubMed ID: 21504337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M; Magder LS
    Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus.
    Elefante E; Tani C; Stagnaro C; Signorini V; Parma A; Carli L; Zucchi D; Ferro F; Mosca M
    Arthritis Res Ther; 2020 Oct; 22(1):241. PubMed ID: 33054823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus.
    Piga M; Floris A; Cappellazzo G; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Res Ther; 2017 Nov; 19(1):247. PubMed ID: 29126432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus.
    Emamikia S; Oon S; Gomez A; Lindblom J; Borg A; Enman Y; Morand E; Grannas D; van Vollenhoven RF; Nikpour M; Parodis I
    Rheumatology (Oxford); 2022 Nov; 61(12):4752-4762. PubMed ID: 35302581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
    Oon S; Huq M; Golder V; Ong PX; Morand EF; Nikpour M
    Ann Rheum Dis; 2019 May; 78(5):629-633. PubMed ID: 30679152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maternal and fetal outcomes of lupus pregnancies: A collective effort by Karnataka Rheumatologists.
    Janardana R; Haridas V; Priya V; Bhat V; Singh Y; Rao VK; Jois R; Srikantiah C; Pinto B; Shobha V
    Lupus; 2020 Oct; 29(11):1397-1403. PubMed ID: 32741300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 2022 Systemic lupus erythematosus remission in clinical practice. Message for Polish rheumatologists.
    Pawlak-Buś K; Leszczyński P
    Reumatologia; 2022; 60(2):125-132. PubMed ID: 35782031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort.
    Gerosa M; Beretta L; Ramirez GA; Bozzolo E; Cornalba M; Bellocchi C; Argolini LM; Moroni L; Farina N; Segatto G; Dagna L; Caporali R
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease Activity and Rate and Severity of Flares During Peripartum Period in Thai Patients With Systemic Lupus Erythematosus: An Age at Diagnosis and Disease Duration Matched Controlled Study.
    Louthrenoo W; Trongkamolthum T; Kasitanon N; Wongthanee A
    J Clin Rheumatol; 2022 Mar; 28(2):e473-e479. PubMed ID: 34176885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between care model and disease activity states and health-related quality of life in systemic lupus erythematosus patients.
    Perea-Seoane L; Agapito-Vera E; Gamboa-Cardenas RV; Guzmán-Sánchez G; Pimentel-Quiroz VR; Reategui-Sokolova C; Medina M; Elera-Fitzcarrald C; Noriega E; Rodriguez-Bellido Z; Pastor-Asurza C; Perich-Campos R; Alarcón GS; Ugarte-Gil MF
    Lupus; 2022 Jan; 31(1):110-115. PubMed ID: 34969318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus.
    Smith EMD; Tharmaratnam K; Al-Abadi E; Armon K; Bailey K; Brennan M; Ciurtin C; Gardner-Medwin J; Haslam KE; Hawley D; Leahy A; Leone V; Malik G; McLaren Z; Pilkington C; Ramanan AV; Rangaraj S; Ratcliffe A; Riley P; Sen E; Sridhar A; Wilkinson N; Hedrich CM; Jorgensen A; Beresford MW
    Rheumatology (Oxford); 2022 Aug; 61(8):3378-3389. PubMed ID: 34894234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LLDAS is an attainable treat-to-target goal in childhood-onset SLE.
    Wahadat MJ; van den Berg L; Timmermans D; van Rijswijk K; van Dijk-Hummelman A; Bakx S; Verkaaik M; Versnel MA; Kamphuis S
    Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34969874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.